Drug Profile


Alternative Names: Canef; Cranoc; Digaril; Fractal; Hovalin; Lescol; Lescol XL; Lipaxan; Lochol; Lymetel; Primesin; SRI 62320; Vastin; XU 62320

Latest Information Update: 21 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer AbbVie; Almirall S.A.; AstraZeneca; Bayer; Berenguer-Infale; Italfarmaco; Mitsubishi Tanabe Pharma Corporation; Novartis; Pierre Fabre; Reliant Pharmaceuticals; Sanofi; sanofi-aventis; Solvay
  • Class Antihyperlipidaemics; Indoles; Monounsaturated fatty acids
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemias; Hypertriglyceridaemia
  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Sep 2015 First Generic equivalent available in USA for Hyperlipidaemia
  • 08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top